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SUMMARY 
Cancer cells rely heavily on glucose to support their aberrant proliferation. 
Interestingly, however, only a subset of cancer types responds to glucose 
deprivation-induced cell death. Little is known of what contributes to cell 
death due to glucose deprivation. In this study, protein phosphatase 2A 
(PP2A) was shown to play a critical role in sensing low glucose levels in 
cancer cells. Glucose deprivation initiates an influx of calcium into the 
cytoplasm uniquely in a subset of cancer cells that are sensitive to glucose 
deprivation and activates the calcium calmodulin-dependent kinase 1 
(CAMK1). This activation, in turn, regulates protein phosphatase 
methylesterase 1 (PPME1), an enzyme responsible for the demethylation 
of PP2Ac (PP2A catalytic subunit), leading to the activation of Receptor-
interacting serine/threonine-protein kinase 1 (RIPK1), which induces 
necroptotic cell death. Importantly, CAMK1, PPME1 and RIPK1 are 
essential for this glucose deprivation-induced necroptosis. Interestingly, a 
subset of cancer cells that are sensitive to glucose deprivation lost the 
ability to sustain intracellular glucose levels after glucose deprivation, and 
this unique metabolic property of cancer cells can be therapeutically 
targeted. Indeed, the combination treatment of STF-31, inhibitor of glucose 
transporter protein type 1 (GLUT1), and thapsigargin that increases 
intracellular calcium concentration induced maximal cell death of these 
sensitive cancer cells without affecting normal cells. My data uncovers a 
novel pathway for cancer glucose metabolism that could be exploited for 
therapeutic purposes in clinical settings.   
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1. INTRODUCTION 
1.1 Cancer cell glucose metabolism 
Most cancer cells are addicted to aerobic glycolysis for rapid proliferation 
and tumor maintenance (Christofk et al., 2008a; Patra et al., 2013). This 
phenomenon is termed the Warburg effect, as Otto Warburg discovered that, 
despite the existence of oxygen, cancer cells still exhibited high glycolytic 
rates (Warburg, 1956). In fact, it has been established that altered glucose 
metabolism is one of the hallmarks of cancer cells (Hanahan and Weinberg, 
2011). One of the major requirements for continuous proliferation of cancer 
cell is energy production. However, aerobic glycolysis is not as efficient as 
oxidative phosphorylation in producing ATP. Therefore, the question is, why 
do cancer cells rely so much on glucose metabolism? The initial findings from 
Warburg suggested that it was due to mitochondrial dysfunction in cancer 
cells that inhibited their ability to enter the tricarboxylic acid (TCA) cycle. 
However, the dysfunctional mitochondrial theory was proven to be incorrect, 
as most cancer cells have functional mitochondria (Ward and Thompson, 
2012). If cancer cells have functional mitochondria, then why do they rely on 
aerobic glycolysis? In addition to energy production, cancer cells also depend 
on a large number of macromolecules for tumor maintenance and proliferation. 
It was suggested that cancer cells rely on glucose metabolism for different 
cellular processes, such as production of nucleic acid, protein synthesis, and 
lipid synthesis (Gatenby and Gillies, 2004; Vander Heiden et al., 2009).  
One of the main reasons cancer cells undergo metabolic reprogramming is 
to divert resources for anabolic pathways (Fujita et al., 2011; Mitsuishi et al., 
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2012).  One of the results of oxidative phosphorylation in mitochondria is the 
production of ROS (Wiseman and Halliwell, 1996). For cancer cells, it is 
important to reduce the mitochondrial respiratory rate. Cancer cells therefore 
rely on the intermediates produced from glycolysis to reduce ROS. Reports 
have suggested that multiple intermediates from glycolysis are used for the 
production of macromolecules and ROS scavenging pathways (Bensaad et al., 
2006; Christofk et al., 2008b; Kurata et al., 2000; Suzuki et al., 1997). One of 
the intermediates produced from glycolysis is G6P (Glucose-6-phosphate). 
G6P initiates PPP (Pentose phosphate pathway) to regenerate NADPH and 
maintain a balance in ROS levels. 
Because glucose is so critical for cell survival, most cancer cells would 
undergo cell death upon glucose deprivation. This thesis research shows that 
not all cancer cells are sensitive to glucose deprivation. Certain cancer cells as 
well as normal cells could survive under glucose deprivation. The question 
addressed in this study was, what is the pathway that differentiates the 
sensitivity to glucose deprivation? 
1.2 Targeting altered glucose metabolism: current therapeutic agents 
There are numerous studies on the mechanisms of altered glucose 
metabolism. Research on changes in glucose metabolism has been directed 
towards targeting glucose metabolic pathways of cancer cells. Unlike cancer 
cells, normal cells can survive with prolonged inhibition of glycolysis because 
they have alternative pathways to ensure survival. Therefore, the side effects 
of glycolytic inhibitors would be less for cancer patients. Hence, studies have 
been directed towards finding a suitable glycolytic inhibitor for cancer patients. 
	  	   4	  
Studies have shown the efficiency of glycolytic inhibitors in mouse models 
(Chan et al., 2011; Ramírez-Peinado et al., 2011). In the research discussed 
below, I have focused on 2-doeoxyglucose (2-DG) a glucose analogue, and 
STF-31, a glucose transport inhibitor for GLUT1. 
1.2.1 Glucose analogue: 2-DG 
The glucose analogue 2-DG competes with glucose in the glycolytic 
pathway. After transport into the cells, 2-DG is phosphorylated by hexokinase 
as 2-DG-6-PO4 (2-DG-6-phosphate) (Wick et al., 1957). But unlike glucose-6-
phosphate, it cannot be metabolized further for glycolysis to proceed. Thus far, 
there is no common consensus on the effect of the accumulation of 2-DG in 
cells. However, accumulation of 2-DG in cells will reduce ATP production 
(Zagorodna et al., 2012; Zhu et al., 2005). Several reports have suggested that 
2-DG causes cell death in cancer cells (Ramírez-Peinado et al., 2011; 
Zagorodna et al., 2012), but 2-DG is still not used commercially as a cancer 
therapeutic agent. It is possible that there are still unanswered questions on the 
effects of accumulated 2-DG in cancer cells. This study has shown that 2-DG 
mimics the effect of glucose, and can rescue cancer cells from cell death upon 
glucose deprivation.  
1.2.2 GLUT1 and the GLUT1 inhibitor, STF-31 
 Glucose transporters is a huge family that includes GLUT1-GLUT12. 
GLUT1-GLUT4 are well characterised in glucose transport and most 
expressed in normal cells of different tissues. But it was discovered that 
GLUT1 is overexpressed in cancer cells (Amann et al., 2009; Younes et al., 
1996), and when successfully inhibited, the glucose supply to the cancer cell is 
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depleted. Therefore, GLUT1 is a promising therapeutic target for glucose 
metabolism. Since GLUT1 is overexpressed in cancer, the efforts have been 
directed towards designing inhibitors targeting GLUT1 (Chan et al., 2011; 
Shibuya et al., 2015). In this study, a GLUT1 inhibitor, STF-31 was used to 
deplete glucose in cancer cells.  
However, because inhibitors targeting glucose metabolism pathways have 
not been quite successful in clinic, and it is possible that they may show better 
synergistic effects with another drug. In this study, STF-31 was used with 
thapsigargin, an inhibitor that prevents the recycling of calcium back into the 
endoplasmic reticulum (ER), to achieve maximum cancer cell death. 
1.3  PP2A family  
1.3.1 Overview of PP2A family  
PP2A is a serine/threonine protein phosphatase that is expressed 
ubiquitously in mammalian cells and is one of the most conserved eukaryotic 
proteins. PP2A is a heterotrimeric protein that consists of a core 
heterodimer/holoenzyme PP2Aa (scaffolding subunit), a PP2Ac (catalytic 
subunit), and various subtypes of regulatory subunits (Ruediger et al., 1992; 
Virshup and Shenolikar, 2009). The interaction of regulatory subunits with the 
holoenzyme determines the subcellular localization, substrate specificity, and 
downstream signaling of the PP2A complex (Cegielska et al., 1994; McCright 
et al., 1996). PP2Ac undergoes posttranslational modifications to determine its 
binding with different regulatory subunits. Posttranslational modification 
includes tyrosine phosphorylation of the amino acid T304 (tyrosine 304) 
and/or T307 of the PP2Ac subunit, and/or the methylation/demethylation of 
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the last (C-terminal) amino acid L309 (leucine 309) of the PP2Ac subunit 
(Janssens et al., 2008; Longin et al., 2007; Ogris et al., 1997) 
1.3.2 Methylation/demethylation of the PP2A catalytic subunit 
L309 of the PP2Ac subunit is methylated by leucine carboxyl methyl 
transferase 1 (LCMT1) (De Baere et al., 1999) to promote PP2A holoenzyme 
assembly (Tolstykh et al., 2000; Wei et al., 2001; Wu, 2000; Yu et al., 2001) 
and the activation of PP2A (Hombauer et al., 2007). Demethylation of L309 is 
by protein phosphatase methylesterase 1 (PPME1) (Lee et al., 1996; Ogris et 
al., 1999), and demethylation is associated with the inactivation of  the PP2A 
complex (Hombauer et al., 2007; Xing et al., 2008). LCMT1 and PPME1 are 
the only known methylase/demethylase enzymes specific for PP2A 
methylation/demethylation. LCMT1 activates PP2A, controls a subset of 
downstream processes in the cell cycle (Lee and Pallas, 2007), and is required 
for cell proliferation (Stanevich et al., 2011). Little is known of the function of 
PPME1, aside from its demethylation of PP2A. Some of the functions of 
PPME1 on cancer cell survival are addressed in this study.  
1.3.3 PP2A activity and its relationship with cancer 
Because carboxyl methylation/demethylation regulates the activity of 
PP2A, and is important in downstream signaling processes, a 
methylation/demethylation switch could affect a wide range of cellular 
processes. Some of the important cellular processes  include cell death (Deng 
et al., 1998), cell cycling (Turowski et al., 1995), calcium signaling (Budde et 
al., 2002), and the regulation of various kinases (Westermarck and Hahn, 
2008). Some of the kinases regulated by PP2A include casein kinase 1 delta	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(CSNK1D) (Swiatek et al., 2004) and segment polarity protein dishevelled 
homolog 2 (DVL2) (Ratcliffe et al., 2000). Carboxyl 
methylation/demethylation of PP2A could therefore affect a wide range of 
cellular processes. Inactivation of PP2A is associated with tumorigenesis. It 
was reported that viral DNA tumor antigens bind to the PP2A core 
heterodimer enzyme to inactivate PP2A and initiate tumor formation (Pallas et 
al., 1990; Ruediger et al., 1992). Later, it was reported that there were 
mutations on PP2A complexes causing tumor formation (Chen, 2005; Shouse 
et al., 2010; Wang et al., 1998). The current study demonstrates that PP2Ac 
demethylation can trigger necroptosis in some cancer cell lines. PP2A 
inactivation has been shown to have proapoptotic properties (Li et al., 2002; 
Lu et al., 2009; MacKeigan et al., 2005; Santoro et al., 1998; Simizu et al., 
2004). It is therefore likely that the effect of PP2A on tumor initiation or 
tumor suppression and its role in cell death is influenced by differences in cell 
types and nutrient sources. However, the role of PP2A in tumor initiation or 
tumor suppression remains unknown, and it is possible that PP2A is important 
in both processes. Thus far, PP2A has not been associated with glucose 
metabolism. In this study, a possible novel role of PP2A as a sensor of glucose, 
is suggested.  
1.4 Calcium signaling 
Calcium signaling is involved in many cellular processes. Research on 
calcium signaling began before the 20th century. Some of the cellular 
processes include muscular contraction (Ebashi and Endo, 1968) and synaptic 
transmission (Harvey and Macintosh, 1940). Calcium signaling has also been 
associated with cell proliferation (Hennings et al., 1980), inhibition of cell 
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proliferation (Buset et al., 1986), and cell death (Furuya et al., 1994). However, 
in cancer, calcium signaling does not yet have a precisely defined role. 
Depending on the cancer cell types, some cancers have overexpressed calcium 
channels, whereas other cancers undergo cell death if overloaded with calcium 
(Monteith et al., 2007).  
1.4.1 Distribution of calcium  
Calcium is tightly controlled in different cellular compartments, as many 
cellular processes are sensitive to stimuli provided by even small changes in 
calcium levels. Extracellular free calcium is maintained at ~1 mM under 
physiological conditions, and maximum extracellular concentrations are 
maintained at approximately 3 mM during external stimuli (Carafoli, 1987; 
Hofer and Brown, 2003; Monteith et al., 2007). Compared with extracellular 
free calcium, at physiological levels, cytosolic calcium is relatively low at 
~100–200 nM (Carafoli, 1987). Upon receiving external stimuli, 
concentrations may increase 10–100-fold, depending on the cell type (Carafoli, 
1987). Intracellularly, calcium is stored in the endoplasmic 
reticulum/sarcoplasmic reticulum)	   (ER/SR) (Somlyo et al., 1985), and the 
concentration of intracellular calcium store differs, based on tissue types 
(ranging from 100 µM to 2 mM) (Bygrave and Benedetti, 1996).  
1.4.2 Calcium channels and transporters 
Numerous research studies of calcium signaling have identified a wide 
range of calcium signaling molecules. During external stimuli, external 
calcium channels are activated and there is an influx of calcium into the 
cytoplasm. There are various calcium channels, including the voltage operated 
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channels (VOC), receptor operated channels (ROC), second messenger 
operated channels (SMOC), the transient receptor potential (TRP)-ion-channel 
family, inositol-1,4,5-triphosphate receptors [Ins(1,4,5)P3R], the ryanodine 
receptors (RYR), and polycystins (Berridge et al., 2003). Most of the calcium 
channels remain closed to prevent influx of calcium into the cytosol (Budde et 
al., 2002). The L-type calcium channel, belonging to the VOC family, 
responds to a signal from external stimuli to induce the opening of the channel 
via phosphorylation at the C-terminus of the L-type calcium channel (Dzhura 
et al., 2000). To close the channel, PP2A dephosphorylates the L-type calcium 
channel. In this study, I observed that one of the VOC L-type calcium 
channels regulates glucose deprivation-induced cell death. 
When it is required, the ER/SR releases intracellular calcium into the 
cytosol via transporters such as Ins(1,4,5)P3R or RYR (Berridge et al., 2003). 
To maintain a low concentration of calcium in the cytosol, calcium is then 
recycled back into the ER/SR via the SERCA [sarco(endo)plasmic reticulum 
Ca++-ATPase] pumps (Berridge et al., 2003). Accumulation of calcium in the 
cytosol induces cell death (McConkey and Orrenius, 1996; Nomura et al., 
2014). Therefore, studies have explored the possibility of targeting calcium 
signaling pathways to induce cancer cell death (Monteith et al., 2007). 
Thapsigargin is an inhibitor of the SERCA pump, that inhibits the recycling of 
calcium back into the ER/SR to cause high cytosolic calcium levels (Furuya et 
al., 1994; Monteith et al., 2007). In this study, the GLUT1 inhibitor, STF-31 
was combined with thapsigargin to induce maximum cancer cell death. 
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1.4.3 Calcium sensitive enzymes 
Calcium signaling cascades start from the entry of calcium into the cytosol 
and subsequent activation of downstream kinases. Increases in cytosolic 
calcium concentrations generate a signal to the major calcium binding protein, 
calmodulin (CaM) (Soderling, 1999). Ca++-CaM modulates different 
downstream effectors; one of them is a serine/threonine kinase, CAMK1 
(Ca++-CaM dependent kinase 1) (Hook and Means, 2001). CAMK1 must be 
fully phosphorylated to be active (DeRemer et al., 1992a; 1992b), and to 
transmit its signal to modulate other downstream effectors. One possible 
effector is PPME1. It was reported that CAMK1 regulates PPME1 to 
inactivate PP2A (Lee et al., 2014). In yeast, CAMK1 crosstalks with PP2A to 
regulate glucose metabolism (Hanyu et al., 2009). In this study, the role of 
CAMK1 in the glucose deprivation-induced cell death pathway was 
determined.  
1.5 Necroptosis 
1.5.1 What is necroptosis? 
Currently, there are three major types of cell death, apoptosis, autophagic 
cell death, and necrotic cell death. Necrosis was previously thought to be a 
process of unregulated cell death. Recently, it was shown that necrosis is 
regulated by a series of molecules, and regulated necrosis is referred to as 
necroptosis (Hitomi et al., 2008; Vandenabeele et al., 2010b). As the term 
necroptosis was only designated after the year 2000, the precise mechanism 
for necroptosis remains unclear. The initiation of necroptosis requires an 
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increase in cytosolic calcium levels (Kroemer et al., 2009; Nomura et al., 
2014), and a decrease in ATP levels (Eguchi et al., 1997; Golstein and 
Kroemer, 2007). The central molecule that is crucial and serves as a marker of 
necroptosis is RIPK1 (Festjens et al., 2007; Holler et al., 2000; Kroemer et al., 
2009).  
1.5.2 RIPK1 is a marker of necroptosis 
RIPK1 [receptor (TNFRSF)-interacting serine-threonine kinase 1] was 
first identified in 1995 as part of a serine/threonine kinase family that contain 
a death domain and is associated with cell death in Saccharomyces cerevisiae 
(S. cerevisiae) (Stanger et al., 1995). RIPK1 is a crucial regulator of cell 
survival and death. It is associated with cell death induced by metabolic stress, 
genotoxic stress, ROS, inflammatory cytokines, and pathogen infections 
(Declercq et al., 2009; Festjens et al., 2007). In some instances, necroptosis 
requires the formation of necrosomes that include two major RIPK molecules, 
RIPK1 and RIPK3 (Declercq et al., 2009). Both RIPKs can be phosphorylated 
to cause the necroptotic cell death response (Vandenabeele et al., 2010a). 
There are reports that some cell death is associated with RIPK1, alone, 
without the involvement of RIPK3 (Festjens et al., 2007; Hitomi et al., 2008; 
Nomura et al., 2014). Even though necrosomes are required for cell death in 
most necroptotic cell death events, much is still unknown regarding whether 
both RIPK1 and RIPK3 are necessary, or if only one of the kinases is 
sufficient for the trigger of necroptotic cell death.  
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1.6 Aims of this study 
1.6.1 Hypothesis 
It is still unknown what determines the sensitivity to glucose deprivation-
induced cell death for cancer cells. It was reported that PP2A 
methylation/demethylation status is involved in glucose sensing in 
S.cerevisiae (Castermans et al., 2012). In Schizosaccharomyces pombe (S. 
pombe), it was also reported that cell division requires CAMK1-like proteins 
to inhibit PP2A activity (Hanyu et al., 2009). Therefore, for the first part of the 
glucose sensing pathway study, we hypothesize that PP2A is a potential 
glucose sensor for cancer cells regulated through calcium and CAMK1 
signaling. It was previously suggested that glucose deprivation and ATP 
depletion leads to necroptosis (Festjens et al., 2007; Golstein and Kroemer, 
2007; Kroemer et al., 2009). I therefore hypothesized that in cancer cells 
sensitive to glucose deprivation-induced cell death would be necroptotic.  
1.6.2 Aims of this study 
1. To identify the cancer cells that are sensitive to glucose deprivation-
induced cell death: Screen cancer cell lines that are sensitive to 
glucose deprivation. 
2. To identify PP2A as a potential sensor for glucose deprivation in 
cancer cells: Screen various cancer cell lines to determine if PP2Ac 
methylation/demethylation occurs universally in all cancer cell lines. 
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Determine if PP2Ac methylation/demethylation is required for 
glucose deprivation-induced cell death. 
3. To determine if LCMT1 or PPME1 are crucial for glucose 
deprivation-induced cell death: Perform a knockdown of LCMT1 or 
PPME1 and observe the effects on cancer cells after glucose 
deprivation 
4. To identify how glucose deprivation regulates PP2A: Knockdown 
CAMK1 and observe if there is any effect on glucose deprivation in 
cancer cells. If there is an effect, identify if glucose deprivation has 
any effect on calcium signaling. Stain cancer cells with calcium-
specific dye to observe if there is an increase in cytosolic calcium 
levels.  
5. To determine if the mode of cell death induced by glucose 
deprivation is apoptosis or necroptosis: Screen for cancer cell death 
markers such as PARP1 [Poly (ADP-ribose) polymerase 1], CASP3 
(Caspase 3), or RIPK1. 
  






MATERIALS AND METHODS 
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2. MATERIALS AND METHODS 
2.1 Cell culture 
2.1.1 Mammalian cells 
U2OS, SaOS2 (human osteosarcoma), SW480 (human colorectal 
adenocarcinoma), U87MG and U251MG (human glioblastoma astrocytoma), 
A549 and H1299 (human lung carcinoma), and IMR90 and WI38 (human 
normal lung fibroblast) cells were purchased from ATCC (American Type 
Culture Collection). All cells were cultured in high glucose Dulbecco’s 
modified Eagle’s medium (DMEM) (Gibco, Life Technologies) unless 
otherwise stated. U251MG cells were cultured in the same conditions, 
supplemented with 1× minimal essential media (MEM) non-essential amino 
acids (Gibco Life Technologies), and 1× sodium pyruvate (Gibco Life 
Technologies). SW480 cells were cultured in high glucose Roswell Park 
Memorial Institute (RPMI) 1640 media (Gibco Life Technologies). All media 
were further supplemented with 10% fetal bovine serum (FBS) (Thermo 
Science), 100 units of penicillin, and 100 µg/mL of streptomycin (Gibco Life 
Technologies) and cultured in 5% CO2, in a humidified atmosphere at 37°C 
unless otherwise stated. 
2.1.2 Transfection via the calcium phosphate method 
Cells were transiently transfected with siRNA according to the standard 
calcium phosphate method as previously described (Kingston et al., 2003). 
Briefly, siRNA were collected and added in a drop by drop manner to CaCl2 
(final concentration 12.5 mM) at room temperature. The plasmid mixture was 
placed on a vortex and 2× HBS (HEPES-based buffer, containing 54.55 mM 
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HEPES, 274 mM NaCl, and 1.5 mM Na2HPO4, pH 7.0)	  was added drop by 
drop. Incubation was for several minutes, and the mixture was then added to 
the cells. On the following day, the cells were washed once with 1× 
phosphate-buffered saline (PBS) containing ethylenediaminetetraacetic acid 
(EDTA), and the calcium phosphate containing media was replaced with fresh 
media.  
2.1.3 Glucose deprivation assay 
Because serum contains glucose, cells were treated with media that did not 
contain glucose and serum. U2OS cells were deprived of serum and glucose 
for 3 hours. SW480, SaOS2, U87MG, U251MG, A549, H1299, IMR90, and 
WI38 cells were deprived of serum and glucose for overnight. As a control, 
cells were treated with their respective media containing 10% serum (FBS) 
and glucose concentration as indicated in each respective media (25 mM). 
2.1.4 Addition of dialyzed fetal bovine serum (FBS) to the cells 
Because the dialyzed FBS (GE Healthcare Hyclone) still contained less 
than 1 mM of glucose, further dialysis was required to reduce the amount of 
glucose without affecting the concentration of growth factors. To further 
dialyze the FBS, a slide-A-lyzer G2 dialysis cassette [10k MWCO (10,000 
molecular weight) as a cut-off] was used. Dialysis was performed in ice cold 
1× PBS buffer, overnight in a cold room.  
2.1.5 UV irradiation assay for cells 
To induce apoptosis, U2OS cells were irradiated with 6000 µJ/cm2 of UV 
light. The cells were incubated in an incubator overnight before lysing the 
cells for immunoblotting.  
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2.1.6 Different drug treatments for the cells 
The glucose analogues, 2-deoxy-D-glucose (2-DG), fructose, 6-deoxy-D-
glucose (6-DG), or glucose (all were added to the cells in 1 mM concentration, 
unless otherwise stated in the figure legends), and N-acetyl-cysteine (NAC, 
added in cells with 1 mM) (all from Sigma-Aldrich) were dissolved in water 
and added to the cells. Cycloheximide (CHX, 100 µM), thapsigargin (TG, 10 
nM), nifedipine (Ni, 25 µM) (all from Sigma-Aldrich), and STF-31 (12.5 µM) 
(Santa Cruz Biotechnology), were dissolved in dimethyl sulfoxide (DMSO) 
and added to the cells in the concentration mentioned in brackets. 
2.2 The siRNA silencing experiments 
All siRNAs were obtained from Ambion unless otherwise stated. Control 
siRNA (on target plus non-targeting pool) were obtained from Dharmacon. 




CCAUAGGUGUCAUCGCCUA, RIPK1_1 GCAAAGACCUUACGAGAAU, 
RIPK1_2, CCACUAGUCUGACGGAUAA. All siRNAs were diluted to a 40 
µM stock solution and further diluted to 20 nM for transfection purpose. 
2.3 Protein analysis 
2.3.1 Cell lysis and immunoblotting conditions  
Cell lysis was done by washing the cells three times with 1× PBS and 
lysing with 2% SDS lysis buffer [2% SDS, 50 mM Tris HCl (pH 6.8) and 10% 
glycerol]. The lysate was passed through a 1 mL syringe with a 27.5 gauge 
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needle, at least 5 times, or until the lysates were no longer viscous. Proteins 
were separated with 11% SDS-PAGE (sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis). After electrophoresis, proteins were transferred onto 
nitrocellulose membranes. The membrane was then blocked in either 5% non-
fat milk (Shoprite) in PBS containing 0.1% Tween-20 [polyoxyethylene (20) 
sorbitan monolaurate] (PBST) for 1 hour at room temperature, or in non-
mammalian Odyssey blocker (LICOR Bioscience).  
2.3.2 Alkaline demethylation assay 
Alkaline demethylation assays were performed as previously described 
(Turowski et al., 1995). Briefly, cells were lysed with 2% SDS lysis buffer 
containing 5M NaOH as described above and incubated in the strong alkaline 
lysis buffer for 30 minutes at room temperature, neutralized with 5 N HCl, and 
subjected to SDS-PAGE.  
2.3.3 Phos-tag acrylamide SDS-PAGE 
Phos-tag acrylamide SDS-PAGE (Wako Pure Chemical Industries, Ltd.) 
was prepared according to the manufacturer’s instructions. After gel 
electrophoresis, the gel was washed three times, each for 10 minutes, with 
transfer buffer containing 1× Tris-glycine, 20% ethanol, and containing 10 
mM EDTA. Finally, the gel was washed with transfer buffer without 10 mM 
EDTA for 10 minutes. Proteins were transferred onto polyvinylidene 
difluoride (PVDF) membranes, and the membrane was then blocked with non-
mammalian Odyssey buffer (Licor Bioscience). 
 
2.3.4 Antibodies and detection methods 
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The following antibodies were used: anti-Dvl2 (clone 30D2, catalogue 
#3224), and anti-CASP3 (catalogue # 9661) (Cell Signaling); anti-De-me 
PP2Ac (clone 4B7, catalogue #sc-13601), anti-CAMK1 (clone H-125, 
catalogue #sc-33165), and anti-TP53 (clone DO1, catalogue #sc-126) (Santa 
Cruz Biotechnology); anti-RIPK1 (clone 38, catalogue #610458) and anti-
PARP1 (clone C210, catalogue #556362) (BD Pharmingen); anti-
PPME1( catalogue #07-095), anti-total PP2Ac (catalogue #07-234), and anti-
actin (clone C4, catalogue #MAB1501) (Merck Millipore); anti-PP2Aa 
(custom made antibody from Professor David Virshup, Duke-NUS); anti-Me 
PP2Ac (custom made antibody from Associate Professor Egon Ogris, Max F. 
Perutz Laboratories); and anti-CSNK1D (custom made antibody from Eli Lily 
Laboratories). The antibodies were prepared and used according to the 
manufacturer’s or provider’s instructions. The diluent for the antibodies was 
the blocking buffer descirbed above: 5% milk blocking buffer or non-
mammalian Odyssey buffer. The membranes were washed three times in 
PBST, then incubated in 5% milk blocking buffer-diluted (1:5000) horse 
radish peroxidase (HRP)-conjugated anti-mouse or anti-rabbit secondary 
antibodies (Jackson ImmunoResearch) for 1 hour at room temperature, 
followed by detection using chemiluminescence (SuperSignal, Pierce). 
Alternatively after washing for 3 times, the membranes were  incubated in 
non-mammalian Odyssey buffer diluted to 1:10000 in infrared fluorescence 
conjugated anti-mouse or anti-rabbit secondary antibodies (Dy-light, Jackson 
ImmunoResearch) followed by infrared fluorescence detection (LI-COR 
Odyssey).  
2.4 Luminescence assay 
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2.4.1 ATP measurement assay 
For ATP measurements, the CellTiter-Glo Luminescent Cell Viability 
assay kit was used (Promega). Cells were lysed with ice cold lysis buffer 
[0.5% NP-40 (nonylphenoxypolyethoxylethanol), 50 mM Tris-HCl (pH 7.5), 
and 150 mM NaCl]. Lysates were collected and analyzed according to the 
manufacturer’s instructions.  
2.4.2 Glucose measurement assay 
The Amplex Red glucose/glucose oxidase assay kit (Life Technologies) 
was used. Cells were lysed and analyzed according to the manufacturer’s 
instructions. Glucose concentration was obtained by comparing against the 
glucose standards as suggested by the manufacturer. Glucose concentration 
was then normalised against the amount of protein used for the glucose 
measurement assay. 
2.5 Fluorescence-activated cell sorting (FACS) analyses 
2.5.1 PI (propidium iodide) staining for cell death  
Cells treated with or without glucose deprivation were stained with PI 
(Sigma-Aldrich) to determine the percentage of cell death. After trypsinization 
of the cells, they were centrifuged, and the pellet was washed once with 1× 
PBS. After centrifugation, the pellet was resuspended in 1× PBS containing 10 
µg/mL of PI. Cells were stained for 15 minutes and data were collected with 
the MACsquant analyzer (Miltenyi Biotec). Quantification and analysis of the 
data were done with Flowjo® software.  
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2.5.2 Reactive oxygen species (ROS) measurement assay  
Cells were treated with or without glucose deprivation, and stained with 
2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) (Life Technologies) to 
detect ROS. After 3 hours of glucose deprivation, cells were trypsinized and 
washed once with 1× PBS. Cells were stained with 10 µM of H2DCFDA 
diluted in phenol red free DMEM for 1 hour. Stained cells were analyzed with 
the MACsquant analyzer (Miltenyi Biotec). Quantification and analyses of the 
data were done with Flowjo® software. 
2.6 Fluorescence microscopy 
2.6.1 Calcium detection assay 
Cells were treated with glucose deprivation and stained with Fluo-4AM 
(Life Technologies). Cells were incubated with phenol red and glucose free 
DMEM for 3 hours, and then Fluo-4AM was added to the cells and incubated 
at 37°C for 15 minutes. Images were obtained with the Olympus IX71 
fluorescence microscope (Olympus) to observe the difference in calcium 
levels before and after glucose deprivation.  
2.6.2 Time-lapse captured images 
Cells were treated with glucose deprivation media and images were taken 
with an IncuCyte ZOOM® (Essen Bioscience) phase contrast microscope. 
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3. RESULTS 
3.1 Identification of cancer cells sensitive to glucose deprivation-induced 
cell death 
Not all cancer cells are susceptible to glucose deprivation-induced cell 
death (Ros et al., 2012; Wellen et al., 2010). In this study, a panel of cancer 
cell lines was screened based on their sensitivity to cell death induced by 
glucose starvation. As serum contains about 0.4 mM glucose, cells were 
incubated in media with or without both glucose and serum. Phase contrast 
microscopy was performed to evaluate the cell morphology after glucose 
deprivation. Five of the seven cell types tested displayed substantial cell death 
in less than 9 hours of glucose and serum starvation (U2OS, U251MG, 
SW480, SaOS2, and U87MG cells) (Figure 3.1A). U2OS cells were 
particularly susceptible to glucose deprivation-induced cell death, as cell death 
occurred within 4 hours. Glucose deprivation increased the number of cells 
that were swelling, round, and loosely attached to the plate in the five sensitive 
cancer cell types. In contrast, two cancer cell lines (A549 and H1299), and 
two normal cell lines (IMR90 and WI38) did not have an altered morphology 
(Figure 3.1A). Additionally, to quantify cell death as assessed by PI exclusion 
assay, cells were followed by fluorescence-activated cell sorting (FACS). Five 
sensitive cell types showed increased cell death upon glucose and serum 
deprivation. In contrast, resistant cell types remained impermeable to PI and 
survived for up to one week in serum and glucose free medium (Figure 3.1B 
and data not shown).  
 
 
	  	   24	  
 
 





   
        
            
 
Figure 3.1 Identification of cancer cells sensitive to glucose deprivation-
induced cell death. (A) Images taken by phase contrast microscopy. Scale 
bars, 50 µM. (B) Cells were collected after treatment with or without glucose 
deprivation for 4 hours. Cells were stained with 10 µg/mL of propidium iodide 
(PI) and analyzed via fluorescence activated cell sorting (FACS). Percentage 
indicates cell death percentage. 
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3.2 Glucose deprivation-induced cell death is independent of serum 
depletion. 
The U2OS cells were used for subsequent analyses because they 
displayed the most rapid initiation of cell death (within 1 hour) after glucose 
removal. To determine if glucose deprivation-induced cell death was 
independent on serum deprivation, cell death was measured in dialyzed serum 
with or without glucose. U2OS cells grown in dialyzed serum-containing 
medium without glucose underwent cell death, as measured by PI 
incorporation (Figure 3.2A). Thus, depletion of glucose alone could trigger 
cell death. In the absence of serum, the re-addition of as little as 0.05 mM 
glucose was sufficient to rescue glucose deprivation-induced cell death 




                    
Figure 3.2 Glucose deprivation-induced cell death is independent of 
serum depletion. In both (A) and (B), U2OS cells were subjected to 
propidium iodide (PI) staining. (A) All cells were treated with double dialyzed 
fetal bovine serum (FBS). Cells were also treated with or without glucose for 
4 hours. (B) Cells were treated with glucose from 0–25 mM for 4 hours. 
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3.3 Glucose deprivation-induced cell death is initiated at an early time 
point. 
To understand when cell death was initiated after glucose deprivation, the 
kinetics of U2OS cell death after glucose deprivation were determined. 
Maximal cell death already occurred after 4 hours. Cell death was completed 
by 6 hours after glucose deprivation as measured by phase contrast 
microscopy. The initiation of cell death occurred within 1 hour. Swelling 
began around 1–2 hrs after glucose deprivation.  
 
     
 
   
Figure 3.3 Glucose deprivation-induced cell death is initiated at an early 
time point. U2OS cells were cultured with glucose-deprived media for 6 
hours and measured using the IncuCyte Zoom® max microscope contained in 
an incubator. Images were taken every 10 minutes and continuously recorded 
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3.4 Glucose depletion-induced cell death is independent of ATP depletion, 
glycolysis, and ROS. 
Glucose is one of the sources used for ATP production in cancer cells, 
and depletion of ATP will cause cell death. The 2-DG is an analogue that 
blocks glycolysis and ATP production. Therefore, the cells were treated with 
2-DG to determine if enhancement of ATP depletion would cause cell death at 
a similar rate as glucose deprivation. In the presence of 25 mM glucose, the 
addition of 1 mM 2-DG minimally reduced ATP levels (Figure 3.4A). In the 
absence of glucose and serum, ATP was further depleted and the addition of 1 
mM 2-DG reduced intracellular ATP even further (Figure 3.4A). The most 
surprising observation was that 2-DG completely rescued the cell death 
induced by glucose deprivation, as shown by PI exclusion assays and cell 
morphology (Figure 3.4B and 3.4C). Cell death was attenuated by the addition 
of as little as 0.1 mM 2-DG (Figure 3.4D). The ability of micromolar 2-DG to 
prevent cell death suggests a signaling rather than a metabolic function. Aside 
from ATP depletion, glucose deprivation can induce ROS, and subsequent cell 
death (Aykin-Burns et al., 2009). However, in contrast to other reports, in the 
absence of serum, I did not observe changes in ROS in glucose-deprived cells 
(Figure 3.4E).  
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Figure 3.4 Glucose depletion-induced cell death is independent of ATP 
depletion, glycolysis, and ROS. (A) U2OS cells were treated as indicated for 
4 hours and analyzed for ATP levels. Shown are means ± standard deviations 
(SD) of triplicate samples; ***p<0.001. (B) Cells were treated with 1 mM 2-
DG as indicated for 4 hours and stained with propidium iodide (PI), followed 
by PI exclusion assays and fluorescence activated cell sorting (FACS) 
analyses. (C) Phase contrast microscopy images of cells treated as indicated in 
(B). (D) Cells were cultured in glucose-deprived media, treated with 0.1 mM 
2-DG, and analyzed as indicated in (B). (E) Cells were treated in the absence 
of serum and as indicated for 4 hours, followed by staining with H2CFDA for 
1 hour. Cells were analyzed with FACS. Shown are means ± SD of triplicate 
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samples; **p<0.01. Percentage indicates cell death percentage. 2-DG = 2-
deoxy-d-glucose; Max=maximum. 
 
3.5 Glucose deprivation induces RIPK1 phosphorylation-dependent 
necroptosis. 
To understand the mechanism of cell death induced by glucose deprivation, 
markers of different cell death pathways were measured. Either exposure to 
ultraviolet light (UV) or glucose withdrawal did not trigger apoptotic marker 
expression or cleavage of PARP1 (poly ADP ribose polymerase 1) or CASP3 
(caspase 3) cleavage in U2OS cells (Figure 3.5A). Similarly, addition of 2-DG 
to glucose-deprived cells had no effect on these markers, suggesting loss of 
ATP did not induce apoptosis (Figure 3.5A). Recently, a caspase independent 
form of cell death, necroptosis, was described (Degterev et al., 2005; Kaiser et 
al., 2011). Necroptosis occurred in a receptor-interacting protein (RIP) kinase-
dependent manner (Cho et al., 2009; Duan Wu et al., 2009). Because the 
U2OS cells died in a caspase-independent manner, the marker for necroptosis, 
phosphorylation of receptor-interacting protein kinase 1 (RIPK1) was 
examined (Hitomi et al., 2008). Glucose withdrawal induced a decreased 
electrophoretic mobility of RIPK1 (Figure 3.5B), consistent with other reports 
on the requirement of phosphorylation of RIPK1 to induce necroptosis 
(Cusson-Hermance, 2005). The treatment with 2-DG also reduced RIPK1 
phosphorylation (Figure 3.5B). I hypothesized that, if RIPK1 was required for 
cell death upon glucose withdrawal, then knockdown of RIPK1 by RNAi 
would prevent glucose deprivation-induced cell death. The efficiency of the 
RNAi against RIPK1 was verified with two independent siRNAs (Figure 
3.5C). Next, U2OS cells were transfected individually, and the effects of 
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RIPK1 knockdown on glucose deprivation-induced cell death were 
determined. As predicted, RIPK1 knockdown restored cancer cell viability 
upon glucose withdrawal (Figure 3.5D). Thus, the data suggest that the 
mechanism of cell ddeath induced by glucose deprivation was RIPK1-
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Figure 3.5 Glucose deprivation induces RIPK1 phosphorylation-
dependent necroptosis. (A) U2OS cells were irradiated with 6000 µJ/cm2 of 
UV or cultured in media as indicated with 1 mM of 2-DG for 4 hours and 
further analyzed by western blotting with the indicated antibodies. (B) Cells 
were cultured as indicated for 4 hours and analyzed according to (A). (C) 
Cells were transfected with two independent siRNAs against RIPK1 and 
treated as indicated for 4 hours, with analyses as described in (A). (D) Cells 
were treated as indicated in (C) followed by staining with propidium iodide 
(PI) and analyses with fluorescence activated cell sorting (FACS). Percentage 
indicates cell death percentage. 2-DG = 2-deoxy-d-glucose; Max= maximum; 
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3.6 Glucose deprivation induces PP2Ac demethylation. 
In addition to RIPK1, additional proteins, including casein kinase 1δ 
(CSNK1D) and segment polarity protein dishevelled homolog (DVL2), were 
also markedly phosphorylated after glucose depletion (Figure 3.6A). As these 
proteins are targets of serine/threonine kinases, I hypothesized that there was a 
reduced activity of an upstream serine/threonine phosphatase(s). One of the 
most ubiquitously expressed phosphatases in eukaryotes, protein phosphatase 
2A, is known to regulate the phosphorylation of both of these substrates 
(Ratcliffe et al., 2000; Swiatek et al., 2004). The activity of PP2A can be 
regulated by demethylation of its catalytic subunit, PP2Ac (Hombauer et al., 
2007; Xing et al., 2008). Indeed, after glucose withdrawal, there was a 
substantial increase in PP2Ac demethylation (Figure 3.6B). There was no 
change in the protein levels for the scaffolding subunit, PP2Aa, after glucose 
deprivation (Figure 3.6B). To identify the population of demethylated PP2Ac 
induced by glucose deprivation, studies were compared with a positive control 
population. Strong alkaline, NaOH, was used to treat the cell extracts to fully 
demethylate PP2Ac, and to serve as a positive control (Turowski et al., 1995). 
In comparison, there was an estimated 30% of total PP2Ac that underwent 
demethylation after glucose withdrawal (Figure 3.6B). Thus, demethylation of 
PP2Ac may trigger RIPK1 dependent necroptosis. Consistently, all of the 
cancer cell lines that were sensitive to glucose deprivation-induced cell death 
displayed increased PP2Ac demethylation and RIPK1 phosphorylation upon 
glucose withdrawal (Figure 3.6C). In contrast, the cancer cell lines and the 
normal cell lines that were resistant to glucose deprivation-induced cell death 
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had low levels of demethylated PP2Ac, and there was no measurable RIPK1 
phosphorylation (Figure 3.6C).  
                  
 
Figure 3.6 Glucose deprivation induces PP2Ac demethylation. (A) U2OS 
cells were cultured in media as indicated for 4 hours and analyzed with 
western blotting followed by probing with the indicated antibodies. (B) Cells 
were treated and analyzed as indicated in (A). Lysates in the third lane were 
treated with 5 N NaOH for 30 minutes and neutralized with 5 N HCl. Fold 
change indicates band intensity of demethylated PP2Ac normalised against 
band intensity of total PP2Ac. (C) Cells were treated and analyzed as indicated 
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3.7 PP2Ac demethylation is independent of glycolysis. 
Results demonstrated that 2-DG inhibited PP2Ac demethylation, consistent 
with its ability to inhibit glucose deprivation-induced cell death (Figure 3.7A). 
Minimal doses of glucose at 0.025 mM and low doses of 2-DG at 0.1 mM 
attenuated PP2Ac demethylation (Figures 3.7B and C). These results are 
consistent with Figures 3.2B and 3.4D, and show that glucose and 2-DG can 
rescue cell death. Re-addition of glucose to dialyzed serum also completely 
rescued PP2Ac demethylation (Figure 3.7D), consistent with the results shown 
in Figure 3.2A, demonstrating that the addition of glucose, alone, is sufficient 
to rescue cell death. This suggests that glucose deprivation results in PP2Ac 
demethylation. Because pyruvate is the end product of glycolysis and the 
initiator of ATP synthesis in the tricarboxylic acid (TCA) cycle, pyruvate 
rescue of PP2Ac demethylation was assessed. The supplementation of 
pyruvate did not inhibit PP2Ac demethylation (Figure 3.7E). This is consistent 
with the results shown in Figure 3.4A, suggesting that glucose deprivation-
induced cell death is independent of ATP depletion. Together, these data 
suggest that PP2Ac demethylation is closely correlated with glucose-
deprivation induced cell death, and that both are independent of glycolysis and 
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Figure 3.7 PP2Ac demethylation is independent of glycolysis. (A) U2OS 
cells were treated as indicated with 1 mM of 2-DG for 4 hours and analyzed 
with western blotting followed by probing with the indicated antibodies. (B) 
Cells were treated with increasing doses of glucose for 4 hours and analyzed 
as indicated in (A). (C) Cells were treated with increasing doses of 2-DG for 4 
hours and analyzed as indicated in (A). (D) Cells were treated as indicated for 
4 hours and analyzed as described in (A). (E) Cells were treated as indicated 
for 4 hours with 1 mM pyruvate and analyzed as described in (A). 2-DG = 2-
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3.8 PP2Ac demethylation leads to glucose deprivation-induced RIPK1 
phosphorylation.	  
To determine if PP2Ac demethylation leads to glucose deprivation-induced 
necroptosis, a time course experiment tracing glucose deprivation revealed a 
reproducible PP2Ac demethylation that was initiated at approximately 15 
minutes and increased from 1 hour onwards, following glucose deprivation 
(Figure 3.8A). In this study, RIPK1 phosphorylation occurred after PP2Ac 
demethylation (Figure 3.8A). These data suggested that PP2Ac demethylation 
precedes RIPK1 phosphorylation. To determine if PP2Ac demethylation 
precedes RIPK1 phosphorylation, RIPK1 was knocked down and the PP2Ac 
demethylation pattern was determined. Knockdown restored cancer cell 
viability as shown in Figure 3.5E, but did not affect glucose deprivation-
induced PP2Ac demethylation (Figure 3.8B). These data indicate that glucose 
deprivation induces PP2Ac demethylation and leads to RIPK1 
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Figure 3.8 PP2Ac demethylation leads to glucose deprivation-induced 
RIPK1 phosphorylation. (A) U2OS cells were cultured in glucose-deprived 
media and analyzed in a time course manner with western blotting, followed 
by probing with indicated antibodies. Time indicated are in minutes. (B) Cells 
were transfected with two independent RIPK1 siRNAs. Cells were cultured in 
glucose-deprived media for 4 hours and analyzed as described in (A). De-Me 
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3.9 PP2Ac demethylation is required for glucose depletion-induced cell 
death. 
Thus far, there is still no direct evidence that indicates whether PP2Ac 
demethylation is required for glucose deprivation-induced cell death. The only 
enzyme known to demethylate PP2Ac is PPME1 and there is no other known 
substrate of PPME1 (Lee et al., 1996; Xing et al., 2008). To determine if 
PP2Ac demethylation is required for cell death, PPME1 was knocked down 
and cell death status was monitored after glucose withdrawal. After glucose 
withdrawal, PPME1 knockdown efficiently decreased PP2Ac demethylation, 
RIPK1 phosphorylation (Figure 3.9A), and cell death (Figures 3.9B and 3.9C). 
Time lapse microscopy images also showed that knockdown of PPME1 
significantly delayed cell death (Figure 3.9D). Together, the data reveal that 
PP2Ac demethylation by PPME1 is necessary for glucose deprivation-induced 
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Figure 3.9 PP2Ac demethylation is required to induce cell death upon 
glucose deprivation. (A) U2OS cells were transfected with two independent 
siRNAs against PPME1 and treated as indicated for 4 hours. Lysates were 
analyzed with western blotting and followed by probing with antibodies as 
indicated. (B) Phase contrast microscopy images of cells treated as indicated 
in (A). (C) Cells were treated as indicated in (A) and stained with propidium 
iodide (PI) followed by FACS analyses. (D) Cells were treated according to 
(A) and cultured in glucose-deprived media. Phase contrast microscopy 
images were taken every 10 minutes with the IncuCyte Zoom® microscope. 
Percentage indicates cell death percentage. De-Me= demethylated; 
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3.10 CAMK1 regulates PP2Ac demethylation-induced cell death. 
To investigate the mechanism of how glucose depletion causes PP2Ac 
demethylation and cancer cell death, a kinase inhibitor library that consists of 
81 compounds was screened to identify possible kinase candidates that could 
potentially regulate PP2Ac demethylation. Among these candidates, CAMK1 
(Calcium/calmodulin-regulated kinase 1) is known to be a potential regulator 
of PPME1 in yeast (Hanyu et al., 2009; Lee et al., 2014). In S. pombe, it was 
reported that glucose deprivation activates calmodulin-dependent protein 
kinases (Saitoh et al., 2015). Therefore, the role of CAMK1 in glucose 
deprivation-induced PP2Ac demethylation and necroptosis was assessed. Two 
siRNAs that displayed efficient and specific knockdown of CAMK1 in U2OS 
cells were used (Figure 3.10A), and both CAMK1 siRNAs blocked PP2Ac 
demethylation and cell death upon glucose deprivation (Figures 3.10A and 
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Figure 3.10 CAMK1 knockdown inhibits glucose deprivation-induced 
PP2Ac demethylation and cell death. (A) U2OS cells were transfected with 
two siRNAs against CAMK1 and treated as indicated for 4 hours. Lysates 
were analyzed with western blotting followed by probing with indicated 
antibodies. (B) Cells were treated as indicated in (A) followed by staining with 
propidium iodide (PI) and fluorescence activated cell sorting (FACS) analyses. 
Percentage indicates cell death percentage. De-Me = demethylation; 
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3.11 Calcium influx precedes PP2Ac demethylation and glucose 
deprivation-induced cell death. 
Because CAMK1 is regulated by intracellular calcium concentration 
(Dzhura et al., 2000), the intracellular calcium levels after glucose deprivation 
were determined. U2OS cells were cultured with glucose-deprived media 
followed by staining with the green fluorescent calcium indicator Fluo-4AM. 
Cells cultured in the absence, but not in the presence, of glucose displayed 
green fluorescence, indicating that glucose withdrawal increased the 
intracellular calcium concentration significantly (Figure 3.11A and 3.11B). 
The addition of 2-DG inhibited intracellular calcium concentration 
significantly (Figure 3.11A and 3.11B), consistent with its ability to inhibit 
cell death and PP2Ac demethylation after glucose withdrawal (Figure 3.4B 
and 3.7A). Thus, an increased intracellular calcium concentration correlates 
with PP2Ac demethylation and cell death status regulated by glucose and 2-
DG.  
To characterize the calcium signaling induced by glucose deprivation, time 
lapse microscopy images were acquired to evaluate the kinetics of intracellular 
calcium levels upon glucose withdrawal. The increases of intracellular 
calcium occurred within 15 minutes, preceding the demethylation of PP2Ac 
(Figure 3.11C). When compared to the cells cultured with glucose, cells that 
were glucose deprived stained much earlier with green fluorescence. As the 
calcium dye is linked with acetoxymethyl ester, which is nonspecifically	  
cleaved by esterases after entry into the cells, eventually cells will be stained 
with green fluorescence upon incubation with the dye for a long period of time. 
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This may explain why, over time, the cells cultured with glucose exhibited 
increased green fluorescence staining.  
              
        
        
Figure 3.11 Glucose deprivation increases cytoplasmic calcium levels. (A) 
U2OS cells were treated as indicated for 4 hours followed by staining with 
Fluo-4AM for 15 minutes. (B) Quantification of the green fluorescence was 
done as described in (A). Shown are means ± SD of triplicate samples; 
***p<0.001.  (C) Cells were treated as indicated in (A), and images were 
obtained every 10 minutes with the IncuCyte ZOOM® microscope for 1 hour. 
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3.12 Inhibition of the calcium channel on the plasma membrane rescues 
glucose deprivation-induced cell death. 
There are two main sources of calcium for cells, the exterior source outside 
the plasma membrane, and the intracellular calcium stores of organelles from 
the ER or SR. To determine the source of calcium that inhibits PP2Ac 
demethylation, nifedipine, an antagonist of calcium channels, was used as a 
tool to distinguish the source of the calcium (Gurney et al., 1985). To 
determine the effects of nifedipine as an inhibitor of calcium channels on the 
plasma membrane, cells were cultured together with nifedipine followed by 
Fluo-4AM, and green fluorescence staining, which was significantly reduced 
(Figures 3.12A and 3.12B). If nifedipine inhibits PP2Ac demethylation, this 
suggests that extracellular calcium is important for the pathway of interest in 
this study. Indeed, nifedipine inhibited PP2Ac demethylation and cell death 
(Figures 3.12C and 3.12D). Thus, extracellular calcium is critical for glucose 
deprivation-induced PP2Ac demethylation and cell death. These data suggest 
a model in which glucose deprivation induces an influx of calcium that 
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Figure 3.12 Nifedipine inhibits glucose deprivation-induced PP2Ac 
demethylation and cell death. (A) U2OS cells were cultured as indicated and 
treated with 25 µM of nifedipine for 4 hours followed by staining with Fluo-
4AM for 15 minutes. (B) Quantification of the fluorescence as described in 
(A). Shown are means ± SD of triplicate samples; ***p<0.001. (C) Cells were 
treated as indicated for 4 hours and analyzed with western blotting followed 
by probing with indicated antibodies. (D) Cells were treated as indicated in (A) 
and stained with propidium iodide (PI) followed by FACS analyses. 
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3.13 Intracellular glucose content is correlated with the sensitivity 
towards glucose deprivation-induced cell death. 
In this study, minimal levels of glucose or 2-DG were sufficient to prevent 
necroptosis. Therefore, I hypothesized that the cell lines resistant to glucose 
deprivation-induced cell death may have higher intracellular glucose content. 
The results demonstrated that resistant cancer cells and non-transformed IMR-
90 and WI-38 cells still maintained higher levels of intracellular glucose as 
compared to sensitive cancer cells after glucose withdrawal (Figure 3.13). 
Thus, intracellular glucose content correlates well with the sensitivity of each 
cell type to glucose removal.  
               
Figure 3.13 Intracellular glucose content correlated with the sensitivity to 
glucose deprivation-induced cell death. Cells were cultured in media as 
indicated and lysed for glucose measurement assays. Shown are means ± SD 
of triplicate samples. Glucose concentration (µM) was obtained by comparing 
with the glucose standards and normalised by the amount of protein (µg) used 
for measurement.  
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3.14 Therapeutic intervention targeting calcium signaling and glucose 
deprivation 
It is possible that sensitive cancer cells lose the ability to maintain a 
favourable intracellular glucose level under low glucose conditions, making 
them more sensitive to therapeutic intervention. The effect of a glucose 
transport inhibitor on sensitive cell lines was therefore investigated. The 
sensitive cancer cells may not be able to maintain intracellular glucose content 
under low glucose conditions, and therefore would be more sensitive to the 
inhibitor. The effect of STF-31, an inhibitor of the glucose transporter GLUT1 
was assessed. STF-31 alone did not induce PP2Ac demethylation in U2OS 
and WI-38 (Figure 3.14A). However, STF-31 alone increased cytoplasmic 
calcium concentration significantly, as indicated by Fluo-4 staining in U2OS 
(Figures 3.14B and 3.14C). This is consistent with the kinetics of calcium 
influx into the cytoplasm, occurring earlier than PP2Ac demethylation, as 
shown in Figure 3.11D.  
Based on the findings discussed above, that an influx of calcium promotes 
PP2Ac demethylation, cells were then treated with a combination of STF-31 
and thapsigargin to elevate cytosolic calcium levels. Indeed, cells treated with 
a combination of STF-31 and thapsigargin displayed higher levels of 
demethylated PP2Ac than the cells treated with either drug alone in U2OS 
(Figure 3.14A). I next determined if STF-31 and thapsigargin would act 
synergistically to induce cell death. The combination of STF-31 and 
thapsigargin together caused at least a 3-fold increase in cell death compared 
to either drug alone in U2OS but not in WI-38 (Figure 3.14D). Therefore, it is 
possible to target cancer cells that lack the ability to maintain intracellular 
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glucose levels without affecting normal cells by combining inhibitors that 
target glucose transport, together with inhibitors that enhance cytosolic Ca++ 
accumulation. 
             
         
 
Figure 3.14 Combination of GLUT1 inhibitor and thapsigargin induces 
maximum cell death. (A) U2OS cells and WI-38 were treated as indicated 
with 12.5 µM of STF-31 and/or 10 nM of thapsigargin in 1 mM of glucose 
media for 1 day. Fold change indicates band intensity of demethylated PP2Ac 
normalised against band intensity of total PP2Ac. (B) Cells were treated as 
indicated for 1 day in 1 mM of glucose media with 12.5 µM of STF-31 and 
stained with Fluo-4AM. (C) Quantification of the fluorescence was as 
described in (B). Shown are means ± SD of triplicate samples; **p<0.01.  (D) 
Cells were treated with 12.5 µM of STF-31 and/or 10 nM of thapsigargin as 
indicated in (A) and stained with propidium iodide (PI) followed by FACS 
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4. DISCUSSION 
4.1 Sensitivity of cancer cells to glucose deprivation as depicted by a novel 
CAMK1-PP2A pathway 
Some cancer cell types rely on enhanced glucose metabolism for survival. 
Due to their need for high glucose levels, cancer cells have a substantial 
increase in the uptake and consumption of glucose. With an increase in 
glucose metabolism and use, cancer cells undergo a metabolic switch to 
aerobic glycolysis, termed the “Warburg effect” (Warburg, 1925; 1956). 
Despite what is known about the Warburg effect, in this study I have shown 
that cancer cells have differential sensitivity to glucose deprivation, and this 
sensitivity is independent of the Warburg effect.  
The differential sensitivity to glucose deprivation correlates with 
intracellular glucose content and PP2Ac demethylation. For the cancer cells 
that are sensitive to glucose deprivation, a lack of glucose triggers an increase 
in cytoplasmic calcium levels, leading to CaMK1-dependent PP2Ac 
demethylation. PPME1-mediated demethylation of PP2Ac is crucial for the 
phosphorylation of RIPK1 and necroptosis upon glucose withdrawal. The 
addition of glucose and its analog, 2-DG, rescues the effect of PP2Ac 
demethylation and subsequent necroptosis. Thus, I have found a new 
glucose/calcium/CAMK1/PPME1/PP2Ac/RIPK1 signaling pathway that 
activates necroptosis in response to a lack of glucose. 
4.2 Limitation of 2-DG as a therapeutic agent 
Glucose analogues, including 2-DG, have been examined as potential 
therapeutics due to their ability to inhibit glycolysis (Ben Sahra et al., 2010; 
	  	   51	  
Simons et al., 2007). However the results of the current study demonstrated 
that a minimal amount of glucose (0.05 mM) and 2-DG (0.1 mM) prevents 
cell death in a subset of cells. Considering that normal human blood glucose 
levels are around 5-7 mM, it is unlikely that glucose at these lower 
concentrations serves as a source of energy or building blocks. Rather, this 
suggests that glucose and 2-DG serve as signaling molecules to protect cancer 
cells from cell death. 
Glucose and its analogue may regulate calcium channels on the plasma 
membrane directly or indirectly. A decrease in cellular glucose induces an 
influx of calcium into the cytoplasm and subsequently causes necroptosis. 
These findings that 2-DG can prevent necroptosis in some cancers raises the 
concern that glycolytic inhibitors may have limited success as therapeutics.  
4.3 PP2A plays a role in both tumor suppression and cell death. 
PP2Ac demethylation is associated with inactivation of PP2A, and this 
inactivation of phosphatase activity leads to an increased phosphorylation 
level of downstream kinase substrates (Cho and Xu, 2007). PP2A inactivation 
is widely associated with increased tumor formation (Tolstykh et al., 2000). 
PP2A complexes are inactivated by DNA tumor virus t antigens to cause 
transformation of normal cells to cancer cells (Pallas et al., 1990). Lung and 
colon cancers have mutations in the PP2A scaffolding subunit (Wang et al., 
1998). These findings suggest that PP2A activity is suppressed during tumor 
formation, and its activation is involved in the induction of cancer cell death 
(Perrotti and Neviani, 2006; Westermarck and Hahn, 2008).  
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However, it is not known whether inactivation of PP2A will contribute 
only to tumor formation and inhibition of cell death. The current study 
demonstrates that PP2Ac demethylation is required to trigger necroptosis in 
some cancer cells. A recent report suggested that PP2A inactivation has pro-
apoptotic roles. An inhibitor was designed to inhibit PP2A activity and 
enhance cancer chemotherapy to cause regression in the U87MG xenograft 
model (Lu et al., 2009). A large-scale RNAi screening against phosphatases 
also indicated that knockdown of the catalytic subunit of phosphatases can 
cause cell death (MacKeigan et al., 2005). Active PP2A that is involved in the 
dephosphorylation of Bcl-2 results in resistance to cell death, thus suggesting 
that it is not necessary to inactivate PP2A to inhibit cell death (Simizu et al., 
2004).  
However, inactive PP2A is also associated with the induction of cell death 
(Li et al., 2002; Santoro et al., 1998). Thus, the effect of PP2A on tumor 
suppression, as well as its role in cell death, is likely to be influenced by the 
cancer type. In this study, PP2A is found to have for the first time to have a 
potential role in cell death regulated by glucose levels.  
4.4 Potential role of glucose in calcium channel regulation  
Numerous factors contribute to the increase in cytoplasmic calcium levels 
(Berridge et al., 2000). Currently, little is understood of how, or if, glucose 
regulates the calcium channel at the plasma membrane. For the first time, the 
results of the current study suggest that a nifedipine-sensitive calcium 
channel(s) senses a decrease in intracellular glucose levels. It is known that 
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increases in cytoplasmic calcium levels directly signals CAMK1 and its 
downstream pathways (Soderling, 1999).  
However, the mechanism of how intracellular glucose regulates the 
machinery of calcium channels at the plasma membrane remains to be 
elucidated. Understanding this mechanism could be useful for designing 
therapeutic interventions to inhibit cancer progression. Similarly, it is also 
unclear how Ca++/CAMK1 activity regulates PP2Ac demethylation status. It 
will be important to understand how increased cytoplasmic Ca++/CAMK1 
activity regulates PPME1 to demethylate PP2A.  
It has been established that cytoplasmic calcium is associated with the 
induction of necroptosis (Nomura et al., 2014), and that CAMK2 is activated 
and this leads to the phosphorylation of RIPK1 and necroptosis in 
neuroblastoma cells. However, the role of PP2A was not investigated in this 
study. CAMK1 can regulate PPME1 and inactivate PP2A activity in yeast 
(Hanyu et al., 2009; Saitoh et al., 2015). It has not been shown whether PP2A 
can be inactivated through CAMK1-PPME1 in human cells. Characterization 
of the signaling pathways that can differentiate the levels of glucose may be 
important not only for cancer treatment, but also for other types of cells	  such 
as neurons that rely on glucose for survival. Elucidating this pathway would 
serve multiple purposes, especially in identifying therapeutic targets for 
different diseases. 
4.5 Intracellular glucose content is crucial to determine the sensitivity to 
glucose deprivation-induced cell death. 
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The abilities of different cancer cells to generate or retain residual, 
intracellular glucose may contribute to the differences in sensitivities of 
various cancer cells to glucose deprivation. In my study, I demonstrated that 
cancer cells and normal cells that were insensitive to glucose deprivation had 
relatively high residual, intracellular glucose levels as compared to the cells 
that were sensitive to glucose deprivation. It is known that cancer cells can 
utilize other nutrients for survival to compensate for low glucose supplies 
(Hsu and Sabatini, 2008; Wellen et al., 2010). It is also possible that some 
cancer cells utilize alternative glucose salvage pathways under low glucose 
conditions.  
Cancer cells are known to utilize glycolysis through overexpression of 
glycolytic enzymes such as hexokinase II (HKII) (Rempel et al., 1996). 
Cancer cells may dedicate most of their resources for glycolysis and they may 
have a lower rate of gluconeogenesis for de novo synthesis of glucose. The 
inability to remake glucose could be an Achilles’ heel for some cancers and 
could be therapeutically targeted by enhancing the Ca++-PP2A-necroptosis 
pathway. Because normal cells do not lose the ability of de novo synthesis of 
glucose, enhancing this pathway for therapeutic purposes may have fewer 
treatment side effects. In the future, the molecular signature of cancer cells 
with a reduced ability to produce glucose remains to be elucidated. 
4.6 Therapeutic potential of enhancing the Ca++-PP2A pathway 
Inhibitors that target glucose metabolic flux, such as 2-DG (Ben Sahra et 
al., 2010; Simons et al., 2007) were developed to treat cancer (Tennant et al., 
2010). However, in my studies, it was shown that only a subset of cancer cell 
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types were sensitive to this approach. An alternative approach could be to 
block the uptake of glucose, which could then induce necroptosis in a subset 
of cancers. It would be possible to screen for potential patient samples that 
respond to the inhibition of glucose uptake. Patient tumor samples could be 
obtained and cultured short term in the absence of glucose, and then used to 
evaluate their PP2Ac demethylation status and/or cell death status.  
In addition, combinatorial therapy of a glucose uptake inhibitor and 
another drug may be more effective. The current study demonstrates that a 
combination of GLUT1 inhibitor and thapsigargin induced PP2Ac 
demethylation and necroptosis of U2OS cells in low glucose conditions. STF-
31 have been tested in pre-clinical trials (Chan et al., 2011; Dubois et al., 
2013), and thapsigargin has been used in clinical trials (Doan et al., 2015), but 
the efficacy and toxicity of the combination of GLUT1 inhibitor and 
thapsigargin in vivo remains to be determined. Lastly, the finding that 2-DG 
can prevent cell death in some cancers raises the concern that in some tumor 
types, glycolytic inhibitors may not be useful drug candidates to inhibit tumor 
growth. This study suggests the potential therapeutic value of limiting the 
sensing of glucose in specific cancer cells to induce calcium influx, PP2Ac 
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
5.1 Conclusions 
This study demonstrates a novel pathway triggered by depriving glucose in 
a subset of cancer cells. The pathway induces the influx of calcium and causes 
PP2Ac demethylation. PP2Ac demethylation directly or indirectly induces 
RIPK1 phosphorylation and its associated necroptosis. A subset of cancer cells 
is sensitive to the deprivation of glucose and this is due to the difference in 
intracellular glucose content. The combination of therapeutic inhibitors 
directed against the uptake of glucose and the enhancement of cytoplasmic 
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Figure 5.1 Schematic diagram of deprivation of glucose-inducing cell 
death. Glucose deprivation induces the influx of calcium that results in PP2Ac 
demethylation and RIPK1-dependent necroptosis.  
 
5.2 Future Perspectives 
5.2.1 Testing of the combinatorial drug therapy in vivo 
There are several inhibitors that have been clinically approved, such as 
ritonavir, that are known to be effective in the inhibition of glucose 
transporters (McBrayer et al., 2012; Murata et al., 2000). In the future, the 
efficacy of ritonavir will be assessed in vitro and then validated for therapeutic 
effects in vivo. Cancer cells that are sensitive to glucose deprivation will be 
tested in a tumor xenograft model. The combination of different inhibitors of 
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glucose transporters, along with thapsigargin, will be injected into mice to test 
the combinatorial drug effects.  
5.2.2 Regulation of calcium channels on the plasma membrane by glucose 
It is unknown how glucose regulates the opening of calcium channels on 
the plasma membrane. Therefore, it is necessary to identify the types of 
calcium channels that are affected by intracellular glucose levels. 
Understanding this interaction would be crucial because calcium signaling is 
involved in growth, proliferation, and cell death for many types of cells, 
including neurons and cancer cells. To evaluate the types of calcium channels 
affected by glucose levels, inhibitors for different types of channels will be 
added to cells cultured in the absence of glucose, followed by staining with 
fluorescent calcium-sensing dye, and further analyzed by fluorescent 
microscopy and FACS. 
5.2.3 Potential of targeting glucose metabolism in cancer stem cells 
There is an increasing interest in cancer cells with stem cell-like properties 
(Reya et al., 2001). For a stem cell to maintain its stemness, one of the 
signatures is the need for glucose metabolism (Folmes et al., 2012; Ito and 
Suda, 2014). Therefore, cancer cells with stem-like properties could be 
isolated and treated with glucose deprivation to observe if they have the same 
molecular signatures and phenotypes as reported in this study. In the future, 
the same therapeutic strategies as described in 5.2.1 could be used on these 
cancer stem cells.  
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5.2.4 Comparison of gene expression of glucose deprivation-sensitive 
cancer cells and resistant cancer cells via RNA-seq 
In this study, I predicted that there was likely a difference in the ability of 
de novo synthesis of intracellular glucose that would delineate cancer cells that 
are sensitive or resistant to glucose depletion. However, the fundamental 
genetic differences in cancer cells that are sensitive or resistant to glucose 
deprivation are still unknown. The genetic information of these cells could be 
analyzed and compared by RNA-seq (Wang et al., 2009). The genes of interest 
could then be obtained after analysis with RNA-seq to understand the 
pathways that contribute to the differences in sensitivity to glucose deprivation.	  	  
5.2.5 CRISPR-Cas9 screening to find a target gene that determines the 
sensitivity to glucose deprivation 
The emergence of the CRISPR-Cas9 gene editing system (Cong et al., 2013) 
has enabled genetic engineering to be precise and convenient. Recently, it was 
possible to use this system for genetic screening (Shalem et al., 2014). 
Because there might be a fundamental difference in the ability of cancer cells 
to de novo synthesize glucose, a panel of metabolic genes such as for glucose-
6-phosphatase, or other genes in the glycogenolysis pathway that are involved 
in the synthesis of glucose, could be edited by using the CRISPR-Cas9 system. 
Cells would be genetically modified with the edited genes to find the target 
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